メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
全並 賢二
医学部・腎泌尿器外科学
h-index
558
被引用数
13
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2006
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(68)
類似のプロファイル
(6)
フィンガープリント
Kenji Zennamiが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Prostate Cancer
100%
Robot-Assisted Prostatectomy
76%
Cystectomy
57%
Partial Nephrectomy
49%
Neoplasm
42%
Molecularly Targeted Therapy
37%
Gamma Urogastrone
37%
Continence
37%
Transitional Cell Carcinoma
33%
Prognostic Factor
30%
Gleason Score
30%
Retrospective Study
28%
Lactate Dehydrogenase
28%
Urinary Diversion
27%
Recurrent Disease
26%
Bleeding
24%
Lymph Node Metastasis
24%
Bladder
23%
Survival Rate
21%
Invasive Bladder Cancer
21%
Neoadjuvant Chemotherapy
21%
Prostate Biopsy
20%
Urinary System
20%
Postoperative Ileus
19%
Primary Tumor
19%
Overall Survival
19%
Ureter
18%
Gene Amplification
18%
Fluorescence in Situ Hybridization
18%
Cyclooxygenase 2
18%
Bone Metastasis
18%
Retroperitoneal Lymph Node Dissection
18%
Prothrombin
18%
Chromogranin A
18%
Extracorporeal
18%
Epidermal Growth Factor Receptor 2
18%
Ileal Conduit
16%
Biopsy
16%
Computer Assisted Tomography
16%
Needle Biopsy
15%
Cause Specific Survival
15%
Cancer Specific Survival
15%
Urine Incontinence
14%
Cell Differentiation
14%
Disease
13%
Bladder Cancer
13%
Prostate Specific Antigen
13%
Nephroureterectomy
12%
Kidney Tumour
12%
Radical Nephrectomy
11%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
56%
Gamma Urogastrone
37%
Pharmacodynamics
37%
Prostatitis
37%
Transitional Cell Carcinoma
34%
Bladder Cancer
31%
Pharmacokinetics
28%
Lymph Node Metastasis
28%
Primary Tumor
20%
Renal Cell Carcinoma
19%
Survival Rate
19%
Lactate Dehydrogenase
18%
Bone Metastasis
18%
Cyclooxygenase 2
18%
Epidermal Growth Factor Receptor 2
18%
Prothrombin
18%
Chemotherapy
18%
Gleason Score
18%
Drug Concentration
18%
Minimum Inhibitory Concentration
16%
Kidney Metastasis
16%
Neoplasm
15%
Cause Specific Survival
13%
Malignant Neoplasm
12%
Immunotherapy
11%
Recurrence Risk
10%
Sunitinib
9%
Androgen Receptor
9%
Tryptophan 2,3 Dioxygenase
9%
Chromogranin A
9%
Piperacillin Plus Tazobactam
9%
Heat Shock Protein 27
9%
Muscle Invasive Bladder Cancer
9%
Docetaxel
9%
Pazufloxacin
9%
Meropenem
9%
Racemase
9%
Clinical Pharmacokinetics
9%
Adverse Event
9%
Biochemical Recurrence
9%
Doripenem
9%
Ureter Stone
9%
Circulating Tumor DNA
9%
Hyperthermia
9%
Bladder Carcinoma
9%
Aptamer
9%
Prostate Hypertrophy
9%
Antibacterial Activity
9%
Disease
7%
Prostate Specific Antigen
7%
Keyphrases
Robot-assisted Radical Prostatectomy
28%
Bladder Transitional Cell Carcinoma
19%
Molecular Targeted Therapy
18%
Cyclooxygenase-2
18%
Human Epidermal Growth Factor Receptor 2 (HER2)
18%
Pentafecta Outcomes
18%
Nerve Sparing
13%
Invasive Bladder Cancer
12%
Survival Rate
10%
Cyclooxygenase-2 Expression
10%
Secondary Bladder Cancer
9%
Risk Factors
9%
Gleason Score
9%
Lactate Dehydrogenase
9%
Tumor Extent
9%
Solitary Brain Metastasis
9%
Gene Amplification
9%
Renal Carcinoid
9%
Deep Ensemble
9%
Castration Resistance
9%
Pharmacodynamics Target Attainment
9%
Growth Resistance
9%
Fluorescence in Situ Hybridization
9%
Robot-assisted Radical Nephrectomy
9%
High-grade Prostate Cancer
9%
Pharmacodynamic Evaluation
9%
Clinical Data
9%
Ensemble Machine Learning
9%
Prostate Cancer Patients
9%
Inferior Vena Cava Thrombectomy
9%
Intracorporeal Ileal Conduit
9%
Bone Metastasis
9%
Castration-resistant Prostate Cancer Cells
9%
Functional Peptides
9%
Stripping Technique
9%
Resistance to Immunotherapy
9%
Urethral Suspension
9%
Intraoperative Navigation
9%
High Complexity
9%
Selective Clamping
9%
Laparoscopic Retroperitoneal Lymph Node Dissection
9%
Initial Prostate Biopsy
9%
Rigid Ureteroscopy
9%
Enhanced Recovery Program
9%
Human Prostate Tissue
9%
Partial Nephrectomy
9%
Transitional Cell Carcinoma of the Urothelium
9%
Mild Hyperthermia
9%
Outcome Patterns
9%
Holmium Laser
9%
